Anti-infective Agents : Antiviral Agents
OSOVA1 “Sovaldi injection” 7%; 20 ml/amp
適應症：與其他藥物併用可以治療成人慢性C型肝炎，對HCV基因型1、2、3或4的療效已經獲得確立。
Usual dose:
Hepatitis C, chronic, Genotype 1 and 4：
400 mg orally once daily in combination with peginterferon alfa and ribavirin 500 mg orally twice daily (weight less than 75 kg) or ribavirin 600 mg orally twice daily (75 kg or greater) for 12 weeks.
Hepatitis C, chronic, Genotype 2：
400 mg orally once daily in combination with ribavirin 500 mg orally twice daily (weight less than 75 kg) or ribavirin 600 mg orally twice daily (75 kg or greater) for 12 weeks.
Hepatitis C, chronic, Genotype 3：
400 mg orally once daily in combination with ribavirin 500 mg orally twice daily (weight less than 75 kg) or ribavirin 600 mg orally twice daily (75 kg or greater) for 24 weeks.
Dose adjustment:
Renal impairment: Mild to moderate, no dose adjustment is necessary
Renal impairment, severe (estimated GFR less than 30 mL/min/1.73 m(3)), or ESRD requiring hemodialysis, no dose recommendations can be made
Hepatic impairment: Mild, moderate, or severe (Child-Pugh class A, B, C), no dose adjustment is necessary
Adverse effect:
Common: diarrhea, anemia, headache, insomnia, Fatigue.
Serious: pancytopenia, increased bilirubin level, depression (Severe), suicidal thoughts, suicide.